Clinical Commander

Back to dossier
uro.pediatric-vur.v1PRODUCTION
uro.pediatric-vur.v1

Pediatric Vesicoureteral Reflux (VUR) — grade I–V; primary / secondary / antenatal-hydronephrosis pathway; prophylaxis / surgical / behavioural management

urologychronicpediatricneonatal
Hard-required inputs
0 / 14
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Pediatric patient (neonate through adolescent) with VUR — primary (familial, idiopathic) vs secondary (PUV, UPJ obstruction, neurogenic bladder); grade I–V determines management ladder (AAP 2011)

Inputs
4
Actions
0
Advance rule
Set
Advance when

engine scope confirmed

Patient inputs (20)

Uncircumcised male infants have ~10× UTI risk in first year vs circumcised; AAP 2012 informed parental decision

Recurrent UTI history drives prophylaxis decision per RIVUR / PRIVENT

Bowel-bladder dysfunction (BBD) is a dominant modifiable risk factor; TREAT FIRST before deciding prophylaxis vs surgery (AAP 2011; RIVUR)

Posterior urethral valves, UPJ obstruction, neurogenic bladder — secondary VUR requires different management (AUA pediatric)

Age stratifies management: <1 yr higher resolution rate; older child observation vs prophylaxis decision uses RIVUR data

Sex stratifies risk — VUR more common in girls; circumcision counseling in uncircumcised males (AAP 2012)

Renal + bladder ultrasound after first febrile UTI 2–24 mo; antenatal hydronephrosis postnatal workup (AAP 2011; NICE NG224)

VCUG = gold-standard for VUR diagnosis and grading; radionuclide cystogram for surveillance (less radiation) (AAP 2011)

UA + catheter / SPA culture in <2 yo for every fever episode (AAP 2011)

Baseline + serial renal function — eGFR by Schwartz; cystatin C if available (KDIGO peds)

Fever in known VUR → STAT UA + culture; febrile UTI on prophylaxis = breakthrough (RIVUR)

Grade I–II low (resolves ~80%); III intermediate; IV–V high (RIVUR prophylaxis benefit; surgical candidacy) (AAP 2011)

All pediatric dosing is weight-based (mg/kg/day) — prophylaxis TMP-SMX 2 mg/kg/day or nitrofurantoin 1–2 mg/kg/day (RIVUR)

TMP-SMX contraindicated in sulfa allergy; choose nitrofurantoin alternative (RIVUR / PRIVENT)

DMSA = gold-standard for renal scarring detection; baseline + surveillance in moderate-high grade VUR

First-degree relative with VUR (~30% sibling risk) — screening US in siblings (AAP 2011)

Antenatal hydronephrosis → postnatal renal + bladder US within 3–7 d (NICE NG224)

Current prophylaxis agent + breakthrough history; breakthrough → switch agent per culture (RIVUR)

Hypertension surveillance — renal scarring can cause HTN; check BP at every visit (AAP)

Surveillance for renal scarring → proteinuria predicts progression (AAP)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (9)

9 need judgement
  • informationalsevereVUR_grade_4_5_high
    VUR grade IV–V (high) — continuous TMP-SMX 2 mg/kg/day OR nitrofurantoin 1–2 mg/kg/day qhs × 6–12 mo (RIVUR / PRIVENT) OR ureteral reimplantation / Deflux for failed prophylaxis or parental preference
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveresecondary_VUR_obstructive_or_neurogenic
    Secondary VUR from PUV / UPJ obstruction / neurogenic bladder — STAT urology; PUV in male infant is surgical emergency; CIC for neurogenic (AUA pediatric)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateVUR_grade_3_intermediate
    VUR grade III (intermediate) — observation vs prophylaxis based on age + sex + UTI history + BBD; RIVUR subgroup analysis informs decision
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderaterenal_scarring_DMSA
    Renal scarring on DMSA — surveillance q2–3 yr; HTN + proteinuria surveillance; lifelong follow-up + pregnancy counseling (AAP 2011)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderatebreakthrough_UTI_on_prophylaxis
    Febrile UTI on continuous prophylaxis → switch agent per culture susceptibility + reassess surgical decision (RIVUR; PRIVENT)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateantenatal_hydronephrosis_workup_postnatal
    Antenatal hydronephrosis → postnatal renal + bladder US at 3–7 d (avoid <48 h false negative) → VCUG if persistent moderate-severe; consider amoxicillin interim prophylaxis in <2 mo pending VCUG (NICE NG224)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildVUR_grade_1_2_low
    VUR grade I–II (low) — observation; ~80% spontaneous resolution; no prophylaxis unless recurrent UTI; annual VCUG / radionuclide cystogram (AAP 2011)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildvoiding_dysfunction_overlay
    Bowel-bladder dysfunction (BBD) overlay — TREAT FIRST before deciding prophylaxis vs surgery; behavioural + PEG laxative + scheduled voiding (AAP 2011; RIVUR subgroup)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmildprimary_VUR_familial
    Primary VUR with familial pattern (first-degree relative VUR ~30%) — sibling screening US (AAP 2011)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

This dossier does not reference any calculators.

Recommended regimen

AAP / AUA / RIVUR / PRIVENT — bowel-bladder dysfunction first → grade-tiered observation vs continuous prophylaxis (TMP-SMX or nitrofurantoin) × 6–12 mo → ureteral reimplantation / endoscopic Deflux + circumcision counseling + breakthrough management
axis: pediatric_vur_management_ladderstep 1 - STEP 1 — Bowel-bladder dysfunction (BBD) TREAT FIRST
Selected step "STEP 1 — Bowel-bladder dysfunction (BBD) TREAT FIRST" — Any VUR grade with bowel-bladder dysfunction (holding / encopresis / constipation)
  • Behavioural therapy — scheduled voiding, double voiding, hydration, posture education
    first line
    lifestyle
    triggers: BBD_overlap
    AAP 2011 / RIVUR — BBD is dominant modifiable risk factor; treat before deciding prophylaxis vs surgery
  • polyethylene glycol 3350 (PEG)
    first line
    osmotic_laxative
    0.4–0.8 g/kg/day PO (max 17 g/day) • PO • once daily
    triggers: constipation_BBD
    AAP — constipation contributes to BBD and UTI risk; PEG first-line in pediatric constipation
    rxcui 221147
  • Route to uro.urinary-incontinence-eval.v1 for full BBD workup
    first line
    pathway
    triggers: BBD_overlap
    AAP 2011 — formal BBD pathway covers ICIQ-like assessment + behavioural ladder

outpatient playbook — drug actions (4)

  1. 1. TMP-SMX prophylaxis (≥2 mo, no sulfa allergy)
    2 mg/kg/day TMP component PO qhs • PO • once daily at bedtime
    trigger: VUR grade III–V with recurrent UTI OR high grade IV–V (RIVUR)
    RIVUR 2014 — ~50% relative reduction in UTI
  2. 2. nitrofurantoin prophylaxis (≥1 mo, alternative)
    1–2 mg/kg/day PO qhs • PO • once daily at bedtime
    trigger: Alternative to TMP-SMX if sulfa allergy OR breakthrough
    PRIVENT 2010
  3. 3. PEG 3350 (constipation)
    0.4–0.8 g/kg/day PO once daily (max 17 g/day) • PO • once daily
    trigger: Constipation + BBD
    AAP — pediatric constipation first-line
  4. 4. amoxicillin (interim prophylaxis <2 mo pending VCUG)
    10 mg/kg/day PO once daily • PO • once daily
    trigger: Antenatal hydronephrosis pending VCUG in <2 mo (TMP-SMX contraindicated)
    AAP

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: VCUG-positive vesicoureteral reflux (grade I–V) — entry to VUR pathway (AAP 2011; AUA pediatric VUR); First febrile UTI 2–24 mo with renal + bladder US findings → VCUG planning (AAP 2011); Recurrent febrile UTI (≥2 in 6 mo OR ≥3 in 12 mo) → VUR workup (AAP 2011).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Pediatric Vesicoureteral Reflux (VUR) — grade I–V; primary / secondary / antenatal-hydronephrosis pathway; prophylaxis / surgical / behavioural management** (uro.pediatric-vur.v1).
Phenotype framing: Primary VUR (familial, idiopathic) vs secondary VUR (PUV, UPJ, neurogenic bladder) vs bowel-bladder dysfunction (no VUR, but recurrent UTI) vs renal scarring vs antenatal hydronephrosis without VUR vs other reflux nephropathy (AAP 2011)
Scope: Pediatric patient (neonate through adolescent) with VUR — primary (familial, idiopathic) vs secondary (PUV, UPJ obstruction, neurogenic bladder); grade I–V determines management ladder (AAP 2011)

No severity triggers fired against current inputs.

Plan

Regimen axis: **AAP / AUA / RIVUR / PRIVENT — bowel-bladder dysfunction first → grade-tiered observation vs continuous prophylaxis (TMP-SMX or nitrofurantoin) × 6–12 mo → ureteral reimplantation / endoscopic Deflux + circumcision counseling + breakthrough management** — step "STEP 1 — Bowel-bladder dysfunction (BBD) TREAT FIRST".
1. Behavioural therapy — scheduled voiding, double voiding, hydration, posture education (lifestyle, first line) — AAP 2011 / RIVUR — BBD is dominant modifiable risk factor; treat before deciding prophylaxis vs surgery
2. polyethylene glycol 3350 (PEG) 0.4–0.8 g/kg/day PO (max 17 g/day) PO once daily (osmotic_laxative, first line) — AAP — constipation contributes to BBD and UTI risk; PEG first-line in pediatric constipation
3. Route to uro.urinary-incontinence-eval.v1 for full BBD workup (pathway, first line) — AAP 2011 — formal BBD pathway covers ICIQ-like assessment + behavioural ladder

Setting playbook (outpatient) — Phenotype VUR grade; BBD-first management; prophylaxis vs surgical decision per RIVUR / PRIVENT / AAP / AUA; annual surveillance; transition to adult care (AAP 2011)
4. TMP-SMX prophylaxis (≥2 mo, no sulfa allergy) 2 mg/kg/day TMP component PO qhs PO once daily at bedtime — VUR grade III–V with recurrent UTI OR high grade IV–V (RIVUR) (RIVUR 2014 — ~50% relative reduction in UTI)
5. nitrofurantoin prophylaxis (≥1 mo, alternative) 1–2 mg/kg/day PO qhs PO once daily at bedtime — Alternative to TMP-SMX if sulfa allergy OR breakthrough (PRIVENT 2010)
6. PEG 3350 (constipation) 0.4–0.8 g/kg/day PO once daily (max 17 g/day) PO once daily — Constipation + BBD (AAP — pediatric constipation first-line)
7. amoxicillin (interim prophylaxis <2 mo pending VCUG) 10 mg/kg/day PO once daily PO once daily — Antenatal hydronephrosis pending VCUG in <2 mo (TMP-SMX contraindicated) (AAP)

Non-pharmacologic actions:
- BBD behavioural therapy — scheduled voiding, double voiding, posture, hydration (AAP 2011)
- Route to uro.urinary-incontinence-eval.v1 for full BBD pathway
- Pediatric urology referral if moderate-high grade / recurrent / scarring
- DMSA scintigraphy if recurrent / high grade
- VCUG / radionuclide cystogram surveillance schedule
- Sibling screening US (AAP 2011)
- Circumcision counseling in uncircumcised male with recurrent UTI (AAP 2012)
- Annual transition planning for adolescents

AVOID / contraindication checks:
- TMP_SMX_AVOID_under_2mo_kernicterus (AAP)
- Nitrofurantoin_AVOID_under_1mo_G6PD_hemolysis (FDA / AAP)
- Nitrofurantoin_AVOID_in_pyelonephritis_no_renal_tissue_penetration (AAP 2011)
- Fluoroquinolones_AVOID_in_children_cartilage (FDA / AAP)
- Tetracyclines_AVOID_under_8yo_permanent_tooth_discoloration (AAP)
- Treat_bowel_bladder_dysfunction_first_before_prophylaxis_vs_surgery_decision (AAP 2011 / RIVUR)
- VUR_grade_3_to_5_with_recurrent_uti_warrants_prophylaxis_trial (RIVUR; PRIVENT)
- Antenatal_hydronephrosis_postnatal_US_at_3_to_7d (NICE NG224)
- Bag_urine_NOT_diagnostic_in_under_2yo_use_catheter_or_SPA (AAP 2011)
- Circumcision_discussion_for_recurrent_uncircumcised_male_balanced_counseling (AAP 2012)
- Secondary_VUR_PUV_surgical_emergency_in_male_infants (AUA pediatric)

Monitoring

Regimen monitoring:
- UA culture for every fever episode in known VUR (AAP 2011)
- BP at every visit renal scarring can cause HTN (AAP)
- renal function annually serum creatinine or cystatin C (KDIGO peds)
- renal bladder US annually if high grade or scarring (AAP 2011)
- VCUG or radionuclide cystogram at 12 to 18mo for resolution (AAP 2011)
- DMSA scintigraphy q2 to 3yr if high grade or scarring (AAP)
- reassess prophylaxis annually trial off after 6 to 12mo (RIVUR / PRIVENT)
- urine protein creatinine ratio annually proteinuria predicts progression (AAP)

Setting (outpatient) monitoring:
- Annual BP + renal function + UA
- VCUG / radionuclide cystogram at 12–18 mo intervals for resolution
- DMSA q2–3 yr if high grade / scarring
- Bowel diary + BBD response

Follow-up plan: Trial off prophylaxis after 6–12 mo if no breakthroughs in moderate; transition to adult care; counsel lifelong HTN surveillance + pregnancy considerations if scarring; family screening for siblings (AAP 2011)
- Close-out criterion: follow-up scheduled

Monitoring phase: Annual re-evaluation; UA + culture for fever episodes; BP each visit; renal function annually; renal + bladder US annually if high grade / scarring; VCUG or radionuclide cystogram at 12–18 mo for resolution; DMSA q2–3 yr if high grade / scarring (AAP 2011)

Disposition

Current setting: outpatient — Phenotype VUR grade; BBD-first management; prophylaxis vs surgical decision per RIVUR / PRIVENT / AAP / AUA; annual surveillance; transition to adult care (AAP 2011)

Disposition criteria:
- Stable on ladder step + annual surveillance (AAP 2011)
- Surgical referral if recurrent breakthroughs / parental preference / failed prophylaxis (AUA)

Escalation triggers (move to higher acuity):
- Febrile UTI on prophylaxis → switch agent + reassess surgical decision
- Worsening hydronephrosis / new scarring → STAT urology
- New hypertension → nephrology evaluation

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [SEVERE] VUR grade IV–V (high) — continuous TMP-SMX 2 mg/kg/day OR nitrofurantoin 1–2 mg/kg/day qhs × 6–12 mo (RIVUR / PRIVENT) OR ureteral reimplantation / Deflux for failed prophylaxis or parental preference
- [SEVERE] Secondary VUR from PUV / UPJ obstruction / neurogenic bladder — STAT urology; PUV in male infant is surgical emergency; CIC for neurogenic (AUA pediatric)
- [MODERATE] VUR grade III (intermediate) — observation vs prophylaxis based on age + sex + UTI history + BBD; RIVUR subgroup analysis informs decision

Citations

- AUA Guideline on Management of Primary Vesicoureteral Reflux in Children (Peters CA et al, J Urol 2010 PMID 20650499). Supporting evidence cited by name: AAP UTI 2011/2016 reaffirmation, RIVUR Trial (NEJM 2014) and PRIVENT Trial for continuous antibiotic prophylaxis, NICE pediatric UTI guidance, DMSA imaging consensus. [PMID:20650499](https://pubmed.ncbi.nlm.nih.gov/20650499/)

Last reconciled with current guidelines: 2026-05-22.
References
  • AUA Guideline on Management of Primary Vesicoureteral Reflux in Children (Peters CA et al, J Urol 2010 PMID 20650499). Supporting evidence cited by name: AAP UTI 2011/2016 reaffirmation, RIVUR Trial (NEJM 2014) and PRIVENT Trial for continuous antibiotic prophylaxis, NICE pediatric UTI guidance, DMSA imaging consensus. — PMID:20650499